RESUMO
Objective To assess the value of 18F-FDG PET-CT in monitoring early chemotherapy response in patients with diffuse large B-cell lymphoma (DLBCL).Methods 56 patients with DLBCL received 18F-FDG PET-CT before and after 2 cycles of chemotherapy (CHOP or R-CHOP protocol).The patients were divided into 3 groups,including complete response group (30 cases),partial response group (18 cases) and no response group (8 cases).The x2 test was performed on comparison of complete remission rate and the t test on SUVmax.Results Complete remission rate of complete response group,partial response group and no response group were 93.33 ％ (28/30),66.67 ％ (12/18),and 12.50 ％ (1/8),respectively (x2 =21.62,P ＜ 0.005).Complete remission rate of complete response group was higher than that of partial response group (x 2 =4.00,P ＜ 0.05).Complete remission rates of complete response group and partial response group were higher than that of no response group (x2 =18.58,P ＜ 0.005; x2 =4.51,P ＜ 0.05).A significant difference was observed in SUVmax of partial response group before and after chemotherapy (17.18±4.68 vs 5.20±3.35,t =14.32,P ＜ 0.001) and no obvious difference was showed in SUVmax of no response group between before and after chemotherapy (16.63±6.49 vs 13.81±5.95,t =2.073 2,P ＞ 0.05).Conclusion 18F-FDG PET-CT is very useful and helpful for predicting early chemotherapy response in DLBCL.
RESUMO
Objective Currently,pediatric 18F-FDG dose and acquisition durations are generally based on coarse extrapolation from adult guidelines.This study sought to determine whether shorter acquisition durations or a lower 18F-FDG injected activity could be used during pediatric 18F-FDG PET/CT examinations while maintaining diagnostic utility.Methods Thirty-six whole-body 18F-FDG PET/CT examinations were performed on 36 patients (weight,13-89 kg,(46.51±5.63) kg; age range,3-14 years old,(9.22±3.16) years old) with a weight-based injected activity (5.3 MBq/kg (0.144 mCi/kg)),fixed acquisition durations 180 S/FOV,VIP record acquisition mode using Discovery STE.For each examination,the Vip-mode data was truncated to form multiple datasets with shorter acquisition durations down to a minimum of 60 s/FOV (i.e.,60,80,100,120,140,160 s/FOV data were formed from single 180 s/FOV acquisition).168 image volumes were generated,randomized,and reviewed in a masked manner with corresponding CT image volumes by 6 radiologists.Overall,subjective adequacy and objective lesion detection accuracy by body region were evaluated.Results All examinations with maximum acquisition duration were graded as adequate and were used as the reference standard for detection accuracy.For patients more than 30 kg,when acquisition duration was more than 120 s/FOV,all PET/CT examinations were graded as adequate for clinical tasks,whereas,when acquisition duration was reduced to less than 120 s/FOV,lesion detection became less accurate.For patients less than 30 kg,lesion detection accuracy was perfect for acquisition times between 140 s/FOV and 180 s/FOV for all regions of the body.However,lesion detection became less accurate when imaging acquisition time was reduced less than 140 s/FOV.Conclusions When GE Discovery STE PET/CT was applied during pediatric PET/CT examination,using decreased acquisition times as a surrogate for 18F-FDG dose,18F-FDG dose can be reduced by approximately 33.33％ when patients weigh over 30 kg were scanned for 180 s/FOV.For patients less than 30 kg,18F-FDG dose can be reduced by approximately 22.22％ without losing diagnostic quality.Reduction of overall scan time potentially reduces motion artifacts,improves patient comfort,and decreases length of sedation.Alternatively,decreased 18F-FDG dose minimizes radiation risk.
RESUMO
Objective To investigate the inducing effect of acitrotin on the growth and apoptosis of human cutaneous squamous cell carcinoma cell line SCC13 and on caspases expression.Methods Human cutaneous squa-mous cell carcinoma cell line SCC13 was treated with five different concentrations of acitrefin [5×10-7,1×10-6,5×10-6,1×10-5,5×10-5mol/L].Cell proliferation was evaluated by MTT assay.Apoptosis was assessed by en-zyme-linked immunosorbent assay.The cell cycle was assessed by flow cytometry.The protein expressions of caspase-8 and caspase-9 were examined with Western blot.Results Acitretin inhibited the growth ( F = 83.64,96.34 and 123.17, respectively on the first, third and fifth day)and induced the apoptosis of SCC13 cells(F=74.45,107.37,and 64.28, respectively on the first, third and fifth day) in a dose- and time-dependent manner(P<0.05).Acitretin altered cell cycle distribution of SCC13 cells as compared with controls, the G1-phase population increased by 77.66% 72 hours after acitretin treatment, while the control increased only by 63.55%.An active fragment of caspase-8 occurred following 12 hours treatment of acitretin on SCC13 cells, whereas the caspase-9 active fragment occurred 24 hours after acitretin treatment, which increased time-dependently (P<0.01).Conclusion Acitretin plays an important role on the growth inhibition and apoptosis of cutaneous squamous cell carcinoma cells, which may be affected through both Fas receptor way and mitochondria way.
RESUMO
Objective To detect the expression of apoptotic inhibitor protein Livin in different esophageal epithelial lesions and to analyze the relation between the expression of Livin with pathologic characteristics. Methods The expressions of Livin mRNA and Livin protein were detected by real- time fluorescence quantitative PCR and western blot in 40 patients with different esophageal epithelial lesions including normal, atypical hyperplasia, carcino-ma in stiu and invasive carcinoma. Results The expressions of Livin mRNA were progressively increased from nor-mal to invasive carcinoma( 1.00 ± 0. 00,2.26 ± 0.79,7.24 ± 1.06,12.21 ± 2.47 ). There was statistical signifi-cance in Livin mRNA expression among carcinoma in stiu and invasive carcinoma and normal tissues ( P < 0.05 ). Conclusion The expression of Livin is significantly related to the progression of esophageal cancer,which may be a new target for diagnosis and gene treatment of esophageal carcinoma.
RESUMO
Objective By studying Chinese herbal medicine's application in shanxi tumor hospital, the knowledge of its function in tumor treatment was got, and thus provide a reference for clinical and hospital dispensary's work. Methods The prescription data of our hospital from September 2004 to January 2005 were collected for tabulation and analysis. Results Drugs applied are mostly in the category of "regulating and replenishing the vital qi, improving digestion and removing stagnation". Conclusion The application of Chinese herbal medicine in tumor treatment will have a prosperous future.
